Signant Health Holding Corp (Signant) proposes to acquire 100% of the shares in ActiGraph Holdings, LLC (together with its subsidiaries, ActiGraph).
Signant is a US-based evidence generation company that provides services used in clinical trials. Signant does not have a physical presence in Australia but provides electronic clinical outcome assessments (eCOA), clinical trial randomisation and supply management (RTSM) services, and supplementary clinical trial professional services. Signant supplies these services to both contract research organisations (CROs) and directly to pharmaceutical and biotechnology companies.
Ametris (formerly ActiGraph) is a US-based provider of digital health technology (DHT) for clinical trials, specialising in wearables – in particular, wrist-worn wearables and other sensors – which track biovitals and other digital endpoints for patients participating in clinical trials. Ametris does not have a physical presence in Australia but supplies its DHT products in Australia for non-commercial academic research.
10 Apr 2026
16 Apr 2026
Approved
Notification waiver determination published
Signant - ActiGraph (WA-45011) - Notification waiver determination - 16 April 2026.pdf(152.66 KB)